G-protein-coupled receptors (GPCRs) can modulate diverse signaling pathways, often in a ligand-specific manner. The full range of functionally relevant GPCR conformations is poorly understood. Here, we use NMR spectroscopy to characterize the conformational dynamics of the transmembrane core of the b 2 -adrenergic receptor (b 2 AR), a prototypical GPCR. We labeled b 2 AR with 13 CH 3 ε-methionine and obtained HSQC spectra of unliganded receptor as well as receptor bound to an inverse agonist, an agonist, and a G-protein-mimetic nanobody. These studies provide evidence for conformational states not observed in crystal structures, as well as substantial conformational heterogeneity in agonistand inverse-agonist-bound preparations. They also show that for b 2 AR, unlike rhodopsin, an agonist alone does not stabilize a fully active conformation, suggesting that the conformational link between the agonist-binding pocket and the G-proteincoupling surface is not rigid. The observed heterogeneity may be important for b 2 AR's ability to engage multiple signaling and regulatory proteins.
INTRODUCTION
When first characterized in the 1970s, G-protein-coupled receptors (GPCRs) were often viewed as binary signaling proteins. Simple two-state models, with inactive (R) and active (R*) states in equilibrium, could describe most of their known behaviors. However, functional and pharmacological studies during the subsequent three decades have revealed many GPCRs to be very versatile signaling proteins that can modulate the activity of more than one second messenger system, often in a ligand-specific manner. These observations suggest that GPCRs are dynamic proteins that assume multiple distinct conformations depending on the bound ligand, the associated signaling proteins, and the membrane environment (Deupi and Kobilka, 2010; Yao et al., 2009 ). Subsequent biophysical and biochemical studies provided some direct evidence for multiple conformational states for specific GPCRs (Altenbach et al., 2008; Liu et al., 2012; Yao et al., 2006) , and more recent progress in GPCR structural biology has provided the first high-resolution pictures of GPCRs in both inactive and active states (Rasmussen et al., 2011a (Rasmussen et al., , 2011b Rosenbaum et al., 2007) . These crystal structures represent single snapshots of just a few conformational states, however, and relatively little is known about what other conformational states these receptors can adopt, how dynamic each conformational state is, or how different conformational states are stabilized by binding of ligands and associated signaling proteins. This uncertainty poses an obstacle to structure-based drug design for GPCR targets.
The b 2 AR is an ideal model system for investigating the role of GPCR protein dynamics in signaling. The b 2 AR activates more than one G protein and signals through at least one G-proteinindependent pathway, arrestin (Rajagopal et al., 2005) (Figure 1A ). There is a rich diversity of available ligands for the b 2 AR. These ligands are often characterized as inverse agonists that suppress basal activity, full agonists that maximally activate the receptor, partial agonists that produce submaximal activity even at saturating concentrations, and neutral antagonists that occupy the orthosteric binding site but do not affect basal activity (Rosenbaum et al., 2009) (Figure 1B ). To complicate matters further, the efficacy of a ligand may depend on the downstream signaling pathway used to quantify activity. For example, carvedilol is an inverse agonist for the b 2 AR activation of G s but is a partial agonist for b 2 AR activation of arrestin (Wisler et al., 2007) . Finally, the b 2 AR is the only GPCR that has been crystallized in both inactive and G-protein-coupled conformations (Rasmussen et al., 2011b; Rosenbaum et al., 2007) .
The dynamic behavior of proteins is well recognized but often difficult to characterize. Proteins exhibit small-scale (A) The b 2 AR interacts with several signaling and regulatory proteins in an agonist-dependent manner. The b 2 AR can activate the heterotrimeric G proteins G s and G i . G-protein-coupled receptor kinases (GRKs) phosphorylate the agonist-bound receptor, which can subsequently bind to arrestin and be either internalized or signal through the MAP kinase and other pathways. (B) The b 2 AR exhibits basal agonist-independent activation of G s . Drugs that can suppress basal activity are called inverse agonists (for example, carazolol). Neutral antagonists (for example, alprenolol) can block binding of other ligands but do not impose any biological response. Agonists can be divided into two categories: full agonists (for example, BI-167107) and partial agonists. Full agonists produce the full biological response, whereas partial agonists can only produce a partial biological response even at saturating concentrations. These properties are independent of ligand affinity. (C) Schematic free energy landscapes illustrating the energy of the receptor along the activation pathway. The top, middle, and bottom panels show the energy landscape with no ligand bound, with agonist bound, and with both agonist and nanobody 80 (Nb80) bound, respectively. The middle and bottom panels also show the unliganded landscape as a dashed line for comparison. (D) The NMR experiments show that agonist binding to the b 2 AR does not fully stabilize the active conformation, suggesting a relatively weak conformational link between the agonist binding pocket and the G-protein-coupling surface. Results from crystal structures of Metarhodopsin II and double electron-electron resonance (DEER) spectroscopy suggest that covalently bound trans-retinal can stabilize the active state of the G-protein-coupling surface.
movements at the level of amino acid side chains and largerscale movements between domains on timescales ranging from picoseconds to seconds (Henzler-Wildman and Kern, 2007) . As a result, proteins exist in many conformations, each with a distinct energy resulting from intramolecular chemical bonds and noncovalent interactions. Overall, the thermodynamically most favorable conformations predominate. The most stable conformations correspond to those structures likely to be captured in X-ray crystallography. Thus, our view of protein structure is biased toward these stable conformations. However, the less stable (i.e., less populated) conformations may also be important for function (Hansen et al., 2008) . Protein dynamics are often described in terms of a free energy landscape ( Figure 1C ), where the energy is plotted as a function of conformation. The depths of the energy wells determine the relative populations of the various conformational states at equilibrium, and the heights of the barriers determine the rates of transitions between states (Deupi and Kobilka, 2010) . By employing nuclear magnetic resonance (NMR) spectroscopy to study dynamic properties of the b 2 AR, we can begin to understand its energy landscape. In this paper, we present evidence for several conformational states that have not been observed crystallographically. In particular, our studies reveal an alternative inactive conformational state, which exchanges slowly with the crystallographically observed inactive state in the presence of inverse agonists or in the absence of a ligand. Our studies also demonstrate that a receptor bound to an agonist alone is structurally heterogeneous and that the most populated conformation differs from both the inactive conformational states that dominate in inverse-agonist-bound and unliganded receptors and the active states that dominate when the receptor is bound to both an agonist and a G-protein-mimetic nanobody ( Figure 1D ). Figure S1 and Table S1 ). We use molecular dynamics simulations to provide a structural framework in which to interpret these results. For the purpose of illustration and discussion, we will describe the conformational ensembles induced by different ligands using the simple energy landscapes shown in Figure 1C .
RESULTS AND DISCUSSION
Application of NMR Spectroscopy and MD Simulations to Characterize Conformational Dynamics in the b 2 AR NMR spectroscopy has been used to study the structure and dynamics of a range of proteins. Specific labeling of methyl groups, such as the ε-methyl of methionine ( 13 CH 3 ε-Met), has been shown to be an effective method for studying large molecules by NMR (Beatty et al., 1996; Bose-Basu et al., 2004; DellaVecchia et al., 2007) .
13
CH 3 ε-Mets are ideal NMR probes for high-molecular-weight proteins because the length and flexibility of the methionine side chain compensates for the slow tumbling of large proteins, improving the resolution and sensitivity of the spectra (Tugarinov et al., 2003) .
13 CH 3 ε-Mets are also excellent NMR probes for studying conformational changes in the b 2 AR. The b 2 AR has nine methionine residues (not counting the N-terminal methionine, which is removed by signal peptidase) dispersed throughout its primary sequence, many of which are found in the transmembrane region of the receptor ( Figure 2A and Figure S1A available online). This region has not been accessible to study using fluorescence spectroscopy or fluorine NMR, which require the addition of small-molecule probes to surface-exposed cysteines (Liu et al., 2012; Yao et al., 2006) . The location of a peak (also known as the chemical shift or resonance) representing a 13 C-methyl group in an NMR spectrum is dependent on the microenvironment of the methyl in the protein. In proteins, the protons and carbon of 13 C-methyls experience a wide variety of chemical environments depending on local and global protein structure and on solvent exposure (Butterfoss et al., 2010; Wishart, 2011) . As a result, the position of an NMR peak is very sensitive to changes in protein conformation or protein-protein interactions. NMR is also sensitive to molecular motion; if a methyl group is in conformational exchange between two structurally distinct states, the appearance of the peak is dependent on the timescale at which this exchange occurs (Mittermaier and Kay, 2009) . If the exchange between the two states is slow (several milliseconds or more), one observes two distinct peaks representing the two different environments, whereas if the exchange is fast (nanosecond to microsecond), one observes a peak at the weighted average of the two chemical shifts. For methyl groups that exchange conformations in the intermediate time regime (microseconds to milliseconds), the corresponding peaks will be very weak or not visible (Mittermaier and Kay, 2009) . Therefore, NMR spectra can provide information about changes in protein structure as well as the timescales over which the changes occur.
To provide a structural framework for interpreting the results of our NMR experiments, we utilized atomic-level long timescale MD simulations of the b 2 AR. We analyzed an extensive set of simulations-including some reported previously (Dror et al., 2011a (Dror et al., , 2011b and others performed especially for this purpose-with a focus on specific receptor regions and dynamic properties probed by the NMR experiments. These simulations were performed on Anton ), a special-purpose computer designed to accelerate classical MD simulations by orders of magnitude, allowing them to describe conformational changes on much longer timescales than previously possible.
Modified b 2 ARs for NMR Experiments
To study specific regions of the b 2 AR, we prepared a modified b 2 AR (b 2 AR-D5M) by making the following mutations: M40L, M96T, M98T, M156L, and M171L. These methionines, which face the exterior of the receptor (Figure 2A ), were mutated to simplify the spectrum and eliminate signals from 13 CH 3 ε-Mets that do not undergo structural changes when comparing active and inactive structures. Antagonist and agonist binding affinities were determined for b 2 AR-D5M and other modified receptors described below based on saturation and competition binding experiments (see Figures S1B and S1C and Table S1 ). We also determined that b 2 AR-D5M couples efficiently to the G protein G s as determined by a GTPgS-binding assay ( Figure S1D ). We retained Met36 1.35 at the extracellular end of TM1 as a reference because it is facing outward in a region of the protein that does not undergo conformational changes upon activation. The other three methionines that we retained-Met82 2.53 , Met215 5.54 , and To enable characterization of the dynamic features at the cytoplasmic end of TM6, we also created a L272M mutation in b 2 AR-D5M (b 2 AR-D5M-L272M). In the inactive-state crystal structure of the b 2 AR, Leu272 6.34 packs into a pocket formed by residues in TM5 and TM3 ( Figure 2B ), whereas in active-state structures, Leu272 6.34 is solvent exposed ( Figure 2C ) and does not interact with either Nb80 or G s . The L272A mutation is known to lead to constitutive activity (Samama et al., 1993) and structural instability (Gether et al., 1997 ), but we expected that Met would be a better structural substitute for Leu, causing little constitutive activity. Indeed, the L272M mutation in b 2 AR-D5M resulted in only a modest (4-fold) increase in agonist binding affinity (Figure S1B and Table S1 ), whereas the L272A mutation in wild-type b 2 AR leads to an 20-fold increase in binding affinity (Samama et al., 1993) . The agonist binding affinity for b 2 AR-D5M-L272M is indistinguishable from the unmodified b 2 AR and exhibits none of the biochemical instability associated with the constitutively active mutant L272A (Gether et al., 1997) .
b 2 AR-D5M and b 2 AR-D5M-L272M were expressed in methionine-deficient media supplemented with 13 CH 3 ε-methyl-labeled methionine ( 13 CH 3 ε-Met) and purified to homogeneity (see Experimental Procedures). The 13 CH 3 ε-Met resonances from b 2 AR-D5M and b 2 AR-D5M-L272M appear in a region of the cHSQC spectrum that is free of signals from buffer, detergent, or unlabeled b 2 AR protein ( Figure S2 ). We assigned methionines 36, 82, 215, and 279 in b 2 AR-D5M by mutagenesis ( Figure S3 ). 13 CH 3 ε-Met NMR spectroscopy was recently used to investigate the effect of agonists and partial agonists on the structure of the b 2 AR, and the spectral assignment of specific 13 CH 3 ε-Met resonances is in agreement with ours (Kofuku et al., 2012) .
Ligand-Specific Changes in cHSQC Spectra of the b 2 AR Figures 3 and 4 show the assigned cHSQC spectra of 13 CH 3 ε-Met-b 2 AR-D5M and 13 CH 3 ε-Met-b 2 AR-D5M-L272M under the following conditions: unliganded, bound to the inverse agonist carazolol, bound to the high-affinity agonist BI-167107, and bound to both BI-167107 and the G-protein-mimetic nanobody Nb80. Both carazolol and BI-167107 have very long dissociation half-lives (Rasmussen et al., , 2011a . For NMR experiments, these ligands were added in a 10-fold stoichiometric excess over receptor at concentrations that far exceed their K d /K i values. In studies done with purified b 2 AR-D5M under these conditions, the agonist BI-167107 has a dissociation half-life of 403 min and an association half-life of less than 4.4 min ( Figure S1D ). We therefore do not expect to observe conformational heterogeneity due to ligand dissociation and reassociation. All spectra were obtained at room temperature. We used Nb80 as a substitute for the G protein because the substantially smaller size of Nb80 leads to higher resolution in the resulting NMR spectra (large complexes tumble more slowly, leading to line broadening). Recent crystal structures have shown that the receptor conformations stabilized by Nb80 and the G protein (G s ) are very similar (Rasmussen et al., 2011a (Rasmussen et al., , 2011b . The peaks observed in our two-dimensional (2D) spectra are relatively broad and irregularly shaped. This is due in part to the large size of b 2 AR-D5M together with its detergent micelle but may also reflect inherent conformational heterogeneity.
The Met36 1.35 peak is the most intense peak in all spectra (Figures 3 and S3A) . This was expected, as Met36 1.35 is the most solvent-exposed methionine in b 2 AR-D5M and b 2 AR-D5M-L272M. Inactive-and active-state b 2 AR crystal structures show that TM1 does not undergo a major conformational change during activation, so it is not surprising that we observe no ligand-specific change in the chemical shift for Unliganded and Inverse-Agonist-Bound b 2 AR Are Conformationally Heterogeneous With the exception of Met82 2.53 , each of the methionines present in b 2 AR-D5M corresponds to a single peak in the spectra of the unliganded receptor (Figures 3 and S3 ). The positions of these peaks do not change upon binding to the inverse agonist carazolol, and they thus likely correspond to the inactive state of the receptor (Figure 3) .
In contrast, Met82 2.53 , which is located just below the ligandbinding pocket in TM2 (Figure 2A) , is represented by two peaks of moderate intensity (and possibly a third weak peak) in the unliganded and inverse-agonist-bound samples (Figures 3 and  S3B ). The observation of two peaks from Met82 2.53 suggests that its 13 CH 3 ε-methyl is detecting at least two conformations that exchange on a millisecond or longer timescale. Molecular dynamics simulations indicate that, although the Met82 2.53 side chain transitions between different rotameric states, it does so very rapidly, on a nanosecond timescale, which is far faster than the millisecond timescales that would lead to multiple peaks in NMR spectra ( Figure S4 ). The two peaks thus probably reflect larger structural changes in the receptor.
Several factors might contribute to the presence of dual Met82 2.53 peaks, including changes to the rotameric state of Trp286 6.48 or the protonation state of Asp79 2.50 . Long-timescale molecular dynamics simulations offer an alternative explanation.
In certain simulations of the crystallographic inactive state (both with the inverse agonist carazolol bound and with no ligand bound), we observed a transition to an alternative conformation in which the intracellular half of TM7 (Asn318 7.45 -Cys327 7.54 , including the conserved NPxxY motif) rotates 40 clockwise relative to the crystal structure (viewed from the intracellular side) and shifts toward the center of the helical bundle by 3 Å (Figures 5A and 5B ). This conformational change would allow the ε-methyl Met82 2.53 to move into a more hydrophobic environment and increases its distance to the aromatic ring of Trp286 6.48 from 4.5 Å to 7 Å ( Figure 5C ), which would be expected to alter its chemical shift. The conformational change does not alter the chemical environments of the other methionines present in b 2 AR-D5M and b 2 AR-D5M-L272M. Exchange between these two inactive conformations appears to be slow. In roughly 400 ms of unbiased simulation (split roughly evenly between the crystallographic inactive and alternative conformational states), we have observed three transitions from the crystallographic conformation to the alternative conformation and a single reverse transition. Millisecond-timescale exchange between these two conformations in the NMR experiments seems quite plausible, given that rates estimated by MD simulations often differ from experimentally measured ones by several fold (Dror et al., 2010) and that the receptor is surrounded by lipids in the simulations and detergent in the experiments. To further probe these long-timescale events, we performed temperature-accelerated MD simulations of the carazolol-bound receptor. These simulations exhibited repeated transitions between the crystallographic inactive and alternative conformations, with the crystallographic conformation present in a slightly higher population ( Figure S4D ). It should be noted that, although the timescale of transitions between inactive states observed in Table S2 for details about acquisition of NMR spectra. In all spectra, a peak at 1. ] is observed, and we expect this peak represents nonmethionine methyl groups in the receptor that are observed because of the natural abundance 13 C in the sample (see also Figure S2B ).
MD simulations is consistent with our NMR results, we cannot be certain that either state is responsible for the observed chemical shifts for M82.
In Figure 1C , we illustrate the conformational substates observed with NMR as a pair of local minima, corresponding to the crystallographic and alternative inactive states, within the larger well representing inactive conformations. The local minima are separated by a relatively large energy barrier that is responsible for the slow exchange observed in NMR experiments. These inactive substates are themselves dynamic; within each, for example, our simulations exhibit fast exchange between conformations with and without the ionic lock between TM3 and TM6 formed .
Although carazolol binding does not change the relative intensities of the two main Met82 2.53 peaks, it does induce a small shift in their position relative to the unliganded condition (Figure 3) . The aromatic component of carazolol is relatively far away (7-9 Å ) from 13 CH 3 ε-Met82 2.53 and would thus not be expected to influence its chemical shift ( Figure S4A) Figure S4C ).
Agonists Do Not Fully Stabilize an Active Conformation of the b 2 AR
Not surprisingly, all peaks apart from the one corresponding to Met36 1.35 change substantially upon receptor activation, as evidenced by the spectra of receptor bound to both a strong agonist and the nanobody (BI-167107+Nb80) (Figures 3 and 4) . Under this condition, each methionine has one corresponding peak. The peak representing Met279 6.41 is best seen in Figure S3B , where the overlapping Met82 2.53 has been mutated, or in Figure S5 , which shows a one-dimensional (1D) slice. The Table S2 for details about acquisition of NMR spectra). For the spectra with BI-167107 and BI-167107 plus Nb80 bound, a 1D slice illustrates the splitting of the Met272 6.34 . The red line represents the carbon chemical shift where this 1D slice was taken.
peaks are broad and irregular, suggesting that, when in complex with Nb80, the b 2 AR exists in predominantly one conformation with substantial dynamic behavior, as indicated by a single broad energy well in Figure 1C . When only the agonist BI-167107 is bound (Figures 3 and 4) , the spectra indicate the presence of a receptor conformation distinct from those that dominate either when both BI-167107 and Nb80 are bound or when an inverse agonist or no ligand are bound. In the presence of BI-167107 alone, the peaks corresponding to Met82 2.53 , just below the binding pocket, and Met272 6.34 , at the cytoplasmic end of TM6, display only subtle changes from those observed in the BI-167107+Nb80 condition. In contrast, the peaks corresponding to the residues between the binding pocket and G-proteincoupling regions change substantially; the Met215 5.54 peak becomes weaker and shifts upfield, whereas the Met279 6.41 peak disappears from spectra of b 2 AR-D5M. We cannot exclude the possibility that a peak or peaks representing Met279 and Met279 6.41 when comparing agonist alone with no ligand and agonist+Nb80, we observed differences in peak intensities ( Figure 6A ). These observations can be interpreted using an energy landscape ( Figure 1C Figure 6A ).
Again, long-timescale simulations can provide a possible structural explanation consistent with this data. As described previously (Dror et al., 2011a) , b 2 AR with BI-167107 bound, but without an intracellular binding partner, transitioned spontaneously from the crystallographic active state to the crystallographic inactive state in simulation. En route, it pauses in an intermediate state in which TM7 adopts a conformation similar to that seen in inactive structures, but TM5 and TM6 do not (Figures 6 and 7) . In this intermediate conformational state, as in the crystallographic state, the intracellular end of TM6 maintains its separation from TM3, but the intracellular ends of TM5 and TM6 display substantial mobility.
If we assume that the receptor preferentially populates the intermediate state when bound only to a strong agonist, the mobility observed in the intermediate state (Figure 7) explains the weakness of the Met215 5.54 peak and particularly the Met279 6.41 peak. Met279 6.41 , whose side chain points toward TM3 in the inactive crystal structure and toward TM5 in the active crystal structure, displays the greatest mobility in simulations of the intermediate state; its side chain not only transitions between its active and inactive conformations but frequently points out of the helix bundle into the lipids (Figure 7) . Tyrosine Tyr219 5.58 , just below Met215 5.54 , also adopts two distinct side-chain rotamers.
The region of the receptor just above residues Met279 6.41 and Met215 5.54 and just below the binding pocket also displays substantial mobility in the intermediate state. This connector region (Dror et al., 2011a) , particularly residues Phe282 6.44 and Ile121 3.40 , displays a substantially different conformation in active and inactive crystal structures (Rasmussen et al., 2011b) (Figure 2 little; it consistently points out into the lipid bilayer. This is consistent with the NMR spectra, where the Met272 6.34 peaks are similar in the BI-167107-and BI-167107+Nb80-bound conditions. It also explains the strength of the Met272 6.34 peak under these conditions.
The close similarity of the Met82 2.53 peak in the BI-167107-bound and BI-167107+NB80-bound NMR spectra suggests that, in the presence of a strong agonist, the chemical environment around Met82 2.53 near the binding pocket is very similar to that in the fully active-like conformation. This suggests that the conformational coupling between the binding pocket and the cytoplasmic ends of TMs 5 and 6 is relatively weak and is in agreement with simulations showing that the conformation of the ligand-binding pocket is only loosely coupled to the conformation of the remainder of the receptor (Dror et al., 2011a ). However, it should be noted that the absence of , displacing a conserved water molecule linking these two residues (Pardo et al., 2007) and Leu75 7.46 (red) over the course of a simulation of b 2 AR, which transitions from the crystallographic inactive conformation to the alternative inactive conformation after 1.93 ms. The bar at the bottom of the plot illustrates when we see the crystallographic inactive conformation (orange) and the alternative inactive conformation 2 (gray). (C) Distributions of the distance from Cε of Met82 2.53 to the closest nonhydrogen atom in the aromatic ring of Trp286 6.48 , plotted for the crystallographic inactive and alternative inactive conformation. See Figure S4 for additional analysis of these two inactive conformations and Table S3 for additional details about molecular dynamics experiments.
a chemical shift for Met82 2.53 does not exclude the possibility of a conformational change in the binding pocket that does not alter the chemical environment of Met82 2.53 .
We note that, although both our NMR data and the simulations suggest that an intermediate state is more stable than the active state when only the strong agonist BI-167107 is bound, the simulations-unlike the NMR data-suggest that the inactive state is even more stable under these conditions (Dror et al., 2011a) . These simulation results are consistent with a b 2 AR crystal structure with only an agonist bound (Rosenbaum et al., 2011) , which closely matches the inactive structure. These differences suggest that the relative populations of the various states may (A) Peak volumes for individual methionines. Automated 2D line-shape fitting was performed on the spectra using NMRpipe (Delaglio et al., 1995) . From the line-shape analysis, volumes of the different peaks were extracted. The peak volumes were normalized to the peak volume of Met36 1.35 . After extracting peak volumes, we estimated their uncertainties by evaluating the root mean square deviation of the volumes of ten peaks chosen from regions of the spectrum where no signal could be detected in the 2D spectrum, and the uncertainties are shown as error bars. For Met82 2.53 , the peak volumes in the carazolol and the unliganded state are averages of peak intensities of the two most intense Met82 2.53 peaks. Although NB80 would be expected to reduce tumbling of the receptor in solution and thereby weaken signals, we see signals intensify, suggesting a stabilization of the receptor and a more uniform distribution of conformations compared to the agonist bound form (see also Figure S5 (C) Simulations of b 2 AR starting in the active conformation with Nb80 removed spontaneously transition back to the inactive conformation. Top two plots illustrate a transition from the active conformation to the inactive conformation during an MD simulation (adapted from Figure 2 of Dror et al. [2011a] ). The distance distribution of the active conformation is based on simulations of b 2 AR with BI-167107 and Nb80 bound; the inactive state is based on simulations of the carazolol bound receptor; and the intermediate state is based on simulations with only BI-167107 bound, as illustrated in the two top plots. See Table S3 for additional details about molecular dynamics experiments.
be highly sensitive to environmental conditions, including lipids/ detergent, temperature, etc. Indeed, minor changes in the energetics of the different conformational states (e.g., 1-2 kcal/mol) can have substantial effects on their relative populations.
Conclusions
Crystal structures provide snapshots of the b 2 AR at the beginning and end of the activation process. The full range of functionally relevant conformations, however, is difficult or perhaps even impossible to characterize by crystallography. In an effort to investigate the process of receptor activation, we used NMR spectroscopy to monitor the chemical environment of native methionines strategically located between the ligand-binding pocket and the G-protein-coupling interface. Our studies show that the conformational link between the ligand-binding pocket and the G-protein-coupling interface of the b 2 AR is not rigid. The results are compatible with a model ( Figure 1D ) whereby TM7   TM2   TM6   TM6   TM6   TM5   TM5   TM2   TM2   TM7   TM7   TM6   TM6   TM5 Figure 1A ). This is in agreement with recent biophysical studies that suggest biased agonists that preferentially activate the arrestin pathway may have a more limited effect on receptor structure (Kahsai et al., 2011; Liu et al., 2012; Rahmeh et al., 2012) . Our studies highlight the complex role of protein dynamics in signal transduction and raise questions about the universality of the structural changes underlying GPCR signal transduction. Although many aspects of GPCR structure appear to be highly conserved, the dynamic properties we observe may reflect our choice of receptor, its environment, or the specific ligands we employed. Rhodopsin has been the most extensively studied GPCR model system, and there is a wealth of structural and biophysical data that characterize the process of activation (Farrens, 2010; Hofmann et al., 2009; Hubbell et al., 2003) . Several lines of evidence suggest that rhodopsin is somewhat less dynamic than other GPCRs ( Figure 1D ). Covalently bound trans-retinal, for example, appears to be effective at stabilizing the active state of rhodopsin even in the absence of a G protein ( Figure 1D ), as shown by recent crystal structures of Metarhodopsin II and double electron-electron resonance (DEER) spectroscopy studies (Choe et al., 2011; Altenbach et al., 2008) . This, together with the lack of constitutive activity, reflects its highly specialized role in detection of light. For GPCRs activated by peptide ligands, it is possible that a more extensive interface between GPCR and agonist might reduce structural heterogeneity. The effect of the lipid environment and associated signaling proteins (including other GPCRs) will likely also contribute to protein dynamics. Further investigation will be necessary to elucidate such variations and their importance in both cellular signal transduction and GPCR drug design.
EXPERIMENTAL PROCEDURES NMR Spectroscopy of 13 C-ε-methyl-Met-b 2 AR Between 15 and 20 l of Sf9 cells were infected by baculovirus encoding one of the b 2 AR constructs described (see more details in Extended Experimental Procedures) and were grown in methionine-deficient media with 13 C methyllabeled methionine added into the media at 250 mg/l concentration. Subsequently, the cells were lysed, and the receptor was purified by antibody affinity chromatography followed by ligand affinity chromatography and then a final antibody chromatography step. The receptor was dialyzed twice against a buffer containing 20 mM HEPES (pH 7.5), 100 mM NaCl, and 0.1% DDM and was prepared in 98% D 2 O and concentrated to a final volume of 270 ml.
NMR
The HSQC pulse sequence used is a modified version of the basic HC-HSQC experiment as described in Bokoch et al. (2010) . Data were acquired on the 800 MHz Varian INOVA spectrometer at Stanford Magnetic Resonance Laboratory (SMRL) and on the 900 MHz Bruker Avance 2 at the Central California 900 MHz NMR Facility.
For all the samples, except the b 2 AR-365N-construct samples, 128 complex t 1 points were collected; for the b 2 AR-365N sample, only 64 complex t 1 points were collected (see Table S2 ). To allow temperature equilibration, 64 steadystate scans preceded data acquisition, and a relaxation delay of 1.5 s was inserted to allow spin to relax back to equilibrium. The spectra were processed and visualized using NMRPipe/NMRDraw (Delaglio et al., 1995) used WET suppression of this methyl peak in some of the experiments (see Table S2 ). A common threshold, based upon a natural abundance peak at 1.4 ppm [ 1 H] and 19.25 ppm [ 13 C], was chosen for all spectra.
Molecular Dynamics Simulation Methods
We analyzed MD simulations of b 2 AR totaling 588 ms, including 15 previously unpublished simulations (Table S3) as well as previously published simulations (Dror et al., 2011a (Dror et al., , 2011b . We performed all-atom simulations of b 2 AR under the four primary conditions of our NMR experiments: unliganded, bound to carazolol, bound to BI-167107, and bound to both BI-167107 and Nb80. The initial coordinates of unliganded and carazolol-bound simulations were based on a carazololbound b 2 AR crystal structure (PDB entry 2RH1). The initial coordinates of BI-167107-bound simulations, with and without Nb80, were based on the crystal structure of b 2 AR bound to BI-167107 and Nb80 (PDB entry 3P0G).
All simulations included an explicitly represented lipid bilayer, water, and salt ions. We used the CHARMM27 parameter set (MacKerell et al., 1998 (MacKerell et al., , 2004 with a modified lipid force field (Klauda et al., 2010) ; a modification to Asp, Glu, and Arg side chains (Piana et al., 2011) ; and previously designed parameters for carazolol, palmitoyl-cysteine, and BI-167107 Rosenbaum et al., 2011) . Simulations were unbiased, apart from two that used temperature-accelerated MD (Maragliano and Vanden-Eijnden, 2006) to accelerate sampling of the distance between the centers of mass of the backbone atoms of Leu75 2.46 and Pro323 7.50 .
For more details on methods and materials used for this work, see Extended Experimental Procedures.
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